Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022

Harish Nair, Megan Fitzpatrick, Rachel Laufer, Ranju Baral, Amanda Driscoll, Daniel Feikin, Jessica Fleming, Mark Jit, Sonnie Kim, Mihaly Koltai, You Li, Xiao Li, Kathleen Neuzil , Clint Pecenka, Erin Sparrow, Padmini Srikantiah, Justin Ortiz

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.
Original languageEnglish
Number of pages12
JournalVaccine
Early online date28 Sept 2023
DOIs
Publication statusE-pub ahead of print - 28 Sept 2023

Keywords / Materials (for Non-textual outputs)

  • cost effectiveness
  • global health
  • monoclonal antibody
  • rrespiratory syncytial virus
  • vaccine

Fingerprint

Dive into the research topics of 'Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022'. Together they form a unique fingerprint.

Cite this